Once-weekly brexpiprazole for acute schizophrenia
Part of Mental health clinical trials.
This trial tests a new once-weekly version of the medication brexpiprazole, which is designed to relieve symptoms of schizophrenia. If you have experienced symptom flare-ups despite being on antipsychotic medication, this study might help you manage your symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 74 years old.
- You have been diagnosed with schizophrenia, and you are currently having an acute episode of symptoms.
- You are currently hospitalized, or your doctor thinks you need to be in the hospital for your current symptoms.
- Your current symptoms started within the last 2 months.
- You have previously taken antipsychotic medication that helped you, but you stopped taking it and your symptoms came back.
- You are not currently experiencing severe suicidal thoughts or a history of suicidal behavior in the last 2 years.
- You have not been diagnosed with another mental health condition like major depressive disorder or bipolar disorder.
- You have not used illicit substances (except tobacco and caffeine) within the past 6 months.
- You are not allergic to brexpiprazole, and you have not taken it for your current symptoms.
- You do not have significant physical health problems that are not well-controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medication, cariprazine, works as well as an older one, aripiprazole, for people having a recent episode of schizophrenia. Participants will receive one of the two drugs for a set period, and the study will track how well symptoms improve.
This study tests an extended-release form of the medication brexpiprazole, given as an injection, for people with schizophrenia. It aims to see how the drug moves through the body and how safe it is.
This study tests an injectable form of brexpiprazole that stays in the body for a long time. It aims to see if the shot is safe and tolerable for healthy volunteers and people with schizophrenia, and how the body processes it.
This Phase 3 study tests whether brexpiprazole can help treat bipolar depression that has not responded to previous treatments. It compares the study medicine to a placebo (inactive pill) for people with bipolar I or II depression.
This study looks at how well brexpiprazole (Rexulti) works in everyday treatment, and how people feel and function over time. You may be eligible if you’re newly started on Rexulti and have a qualifying mental health diagnosis.
This trial tests a new medication called SEP-363856 over a long period for people with schizophrenia who are currently stable. It looks at how well the drug works and its safety over time.
Hear when a new Acute Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.